Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners - First Agreement Signed for a TULSA-PRO® System Interfaced with a GE Scanner -
EXHIBIT 99.1
Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners
- First Agreement Signed for a TULSA-PRO® System Interfaced with a GE Scanner -
TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed the TULSA-PRO® system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (“MRI”) scanners. Profound subsequently signed the first site agreement for a TULSA-PRO® system interfaced with a GE scanner with Boston’s renowned Xxxxxxx and Women's Hospital.
“Prostate cancer is the second most common cancer diagnosis and a leading cause of mortality in men worldwide1,” explained Xxxx Xxxx, General Manager of MR Clinical Solutions & Research Collaboration at GE Healthcare. “For decades, GE Healthcare has proudly equipped clinicians with advanced MRI technologies to visualize and diagnose prostate cancer. Now, we are proud to enable access to a new tool to help clinicians treat this disease under precise MRI guidance: Profound’s TULSA-PRO®. This noninvasive MRI-guided therapy technology is customized to each patient to target prostate disease and spare healthy tissue, offering significant quality-of-life benefits. This new compatibility demonstrates our continued commitment to high quality imaging to guide precision therapy and improve patient outcomes.”
“As demonstrated by our TULSA-PRO® site agreement with the prestigious Xxxxxxx and Women’s Hospital, this expanded compatibility with GE MR systems will allow us to better leverage the existing MRI scanner installed base, increasing our market access in the United States by approximately 30-to-40%,” said Xxxx Xxxxxxx, Profound’s CEO and Chairman. “TULSA-PRO® is now the first and only prostate therapeutic platform to have achieved compatibility with MRI scanners supplied by all three of the world’s largest manufacturers.”
Reference
1 World J Oncol 2019 Apr 10(2):63-89
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it will have on Profound’s operations, the demand for its products, global supply chains and economic activity in general. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Xxxxxxx Xxxxxx
Investor Relations
xxxxxxx@xxxxxxxxxxxxxxx.xxx
T: 647.872.4849
